DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials (NCT) providing thought leadership in Neurodegenerative Disorders. With more than 25 years of research dedicated to this therapeutic area, Dr. Welsh-Bohmer lends the highest level of scientific expertise to the continued development of effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring later in life.
Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions:
Implications for Social, Linguistic, and Cultural Consistency
by ANZALEE KHAN, PhD; LORA LIHARSKA, MS; PHILIP D. HARVEY, PhD;
ALEXANDRA ATKINS, PhD; DANIEL ULSHEN, BA; and RICHARD S.E. KEEFE, PhD
Emerging consensus in recent literature posits a two-factor structure of negative symptoms in schizophrenia: experiential deficits and expressive deficits.1 This presents a departure from the previous one-factor model by differentiating negative symptoms into two potentially correlated but distinct dimensions.2 Experiential deficits comprise avolition (decreased motivation and lack of interest in daily activities), asociality (social withdrawal and reduced value and interest in social contact), and anhedonia (decreased anticipation and experience of pleasure); expressive deficits comprise blunted affect (decreased emotional expressivity and diminished facial expression) and alogia (poverty of speech).3–6 The implications of this two-dimensional model are far-reaching: recent research suggests that each dimension might have its own distinct underlying causes and clinical and functional correlates.6-8
The expressive-experiential distinction has been shown to have vast importance in relation to functional outcomes in schizophrenia. Specifically, experiential deficits have been shown to be more robust predictors of…
NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders
Durham, North Carolina, October 30, 2017 — NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company, today announced it received a 2017 Fast Track grant from the National Institute of Health (NIH) to study the validation of a performance-based measure of functioning in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease (AD) using NCT’s proprietary technology, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The VRFCAT is a state-of-the-art solution developed to improve clinical trials by detecting functionally meaningful improvements in patient’s everyday lives.
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider
DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani, as Executive Director of Global Medical Innovation. Dr. Pani will guide the company’s development of innovative solutions for clinical trials methodologies and health outcomes.
During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models are now being used in many other countries. As a European Regulator, Dr. Pani has not only been a leading figure for the Approval and Scientific Advice for Central Nervous System products, but also has served as Chair of the Telematics Committee. While in AIFA Dr. Pani worked on the approvals of pharmaceutical products in a broad range of all therapeutic areas including oncology, immunology, cardiovascular and CNS disorders.
“I am privileged to have someone with Dr. Pani’s extraordinary background and expertise in regulatory, academic and industry science come to NeuroCog Trials as we expand the breadth of solutions we offer for clinical trial methodologies. Dr. Pani will have an immediate impact and provide deep insight and perspective into our development of innovative strategies for transforming the current landscape,” said Co-Founder and CEO, Dr. Richard Keefe.
NCT offers clients global and regional study design strategies, protocol advisory and measure selection services as well as technology solutions that maximize opportunities for success by adhering to the highest scientific principles and regulatory standards across all clinical phases. Dr. Pani’s expertise innovating health economics and outcomes research will become a central element of NCT’s services.
Dr. Pani is the author or co-author of hundreds of publications and is an internationally recognized speaker at scientific meetings and conferences. He is also professor of Psychiatry at the University of Miami. In addition, his most recent book, Sustainable Innovation: Medicines and the Challenges for the Future of our National Health Service has been published to acclaim. He has served on the editorial boards of many prestigious scientific journals including Clinical Neuropsychiatry, Italian Journal of Psychiatry and Psychotherapy, and the Italian Edition of the American Journal of Psychiatry.
He received his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois and Georgetown University.
About NeuroCog Trials
NeuroCog Trials (NCT) is a global cognition and clinical assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications. NCT has provided consulting, site screening, rater training and certification, translation, and data services for more than 100 clinical trials in over 25 countries. Founded in 2005, NCT is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.
Innovative platform designed to deliver the highest quality of clinical data, streamline site processes, and improve patient experience
DURHAM, NORTH CAROLINA, JULY 13, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the general availability of its new flagship eCOA platform, NCT Pathway. Developed with input from seasoned clinical investigators, Pathway has the dynamic technical capabilities and user-driven design to meet the needs of virtually any clinical trial, from Alzheimer’s disease and schizophrenia to oncology and cardiology. The platform is currently in use by large sponsors in several late stage clinical trials.
Questions: What is the magnitude of learning effects in patients with schizophrenia receiving placebo on the criterion standard Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB), and can these learning effects be anticipated in individual patients?
Patients with psychotic disorders are often treated with numerous medications, many of which have anticholinergic activity. We assessed cognition in relation to the cumulative anticholinergic burden of multiple drugs included in treatment regimens of participants from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.
Article in JAMA Psychiatry
One of the greatest challenges for the identification of the causes and cures for schizophrenia is the overwhelming heterogeneity of the disorder. Schizophrenia is defined by symptoms that have only weak associations with one another and are found in patients with other illnesses. Further, some of the most devastating symptoms, such as cognitive impairment and amotivation, are present in segments of the healthy general population.
Assessing Functional Capacity using the UCSD Performance-based Skills Assessment (UPSA-2-VIM) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
This poster was presented at the Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT)
15-17 March 2017
Washington DC/Rockville MD
Reliable measurement of functional capacity is critical in assessing the efficacy of treatments for cognitive impairment in a wide range of CNS disorders including
This poster was Presented at the Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT)
15-17 March 2017
Washington DC/Rockville MD
Computerized tests benefit from automated scoring procedures and standardized administrator instructions. These methods can reduce the potential for rater error.